-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
January is a period of intensive disclosure of annual report performance forecasts of major listed pharmaceutical companies
.
On January 26, another group of pharmaceutical companies released performance forecasts one after another.
Overall, the results were mixed
.
Among them, the performance of 3 companies has risen sharply, 1 company is expected to turn losses, 1 company is expected to decline in performance, 1 company is expected to continue losses, and 2 companies are expected to increase losses
.
Qianhong Pharmaceutical released the 2021 annual report performance forecast.
It is expected that the net profit from 2021-01-01 to 2021-12-31 will be 150 million to 210 million yuan, an increase of 213.
62% to 259.
07%, and basic earnings per share of 0.
12 yuan to 0.
16 yuan
.
Net profit in the same period last year was -132 million yuan, and basic earnings per share was -0.
11 yuan
.
The company said that during the reporting period, the company's main business development trend was good, and product sales revenue increased steadily
.
The 2021 annual report performance forecast released by Betta Pharmaceuticals shows that it is expected to achieve a net profit of 380 million to 430 million yuan in 2021, a decrease of 37.
33% to 29.
09%, and a net profit of 606 million yuan in the same period last year
.
During the reporting period, the company's operating capabilities continued to improve, more than 40 research projects continued to advance, and the R&D investment increased compared with the same period of the previous year.
It is estimated that the R&D investment accounted for about 37.
00% to 42.
00% of the operating income
.
The 2021 annual report performance forecast disclosed by Saisheng Pharmaceutical shows that it is expected to achieve a net profit of 356 million to 403 million yuan from January 1, 2021 to December 31, 2021, an increase of 130% to 160%.
Profit of 155 million yuan
.
In addition, the company expects that the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses in 2021 will decrease by 0%-30% compared with the same period of the previous year.
About 106.
15 million yuan
.
Haier Bio released the 2021 annual report performance forecast.
It is expected that the net profit in 2021 will be 799 million yuan to 894 million yuan, an increase of 109.
77% to 134.
77%, and a net profit of 381 million yuan in the same period last year
.
It is reported that the company has maintained high growth under the premise of ensuring profitability and achieved high-quality development.
.
During the reporting period, with the continuous deepening of the Internet of Things strategy, the company continued to invest in research and development to promote innovative iterations of technology and product solutions, accelerated channel and network expansion to expand its competitive advantages in the global market, and continued to accelerate the ecological layout of IoT scenarios to ensure the best user experience.
Double-high growth in IoT solutions business and traditional business
.
The 2021 annual report performance forecast released by Dizhe Pharmaceuticals shows that it is expected to achieve a net profit of about -670 million yuan from 2021-01-01 to 2021-12-31, a decrease of about 14.
15%, and a net profit of -587 million yuan in the same period last year
.
During the reporting period, all of the company's research products are in the research and development stage, and commercial production and sales have not yet been launched, and the company's products have not yet achieved sales revenue
.
In addition, the company continues to invest funds to launch new products into preclinical research and clinical trials; with the advancement of research and development progress, some products in the product pipeline are gradually entering the critical clinical stage, requiring large-scale research and development investment, resulting in The company's R&D expenses continue to increase
.
Olin Bio's 2021 annual report performance forecast, it is expected that from 2021-01-01 to 2021-12-31, it will obtain a net profit of 100 million to 115 million yuan, an increase of 176.
78% to 218.
29%, and a net profit of 36.
1302 million yuan in the same period last year
.
Regarding the reasons for the changes in performance, the company will continue to increase market development efforts in 2021, and the company's sales of adsorbed tetanus vaccine will continue to grow
.
At the same time, in 2021, the company's group A group C meningococcal polysaccharide conjugate vaccine obtained the first batch of release and marketing, bringing sales revenue to the company
.
In addition, a number of new pharmaceutical stocks released performance forecasts on the same day.
For example, Asieris Pharmaceuticals, which has just been listed for 19 days, announced a net profit of -251 million to -211 million, an increase of -1.
69% to 14.
60%; Maiwei Bio also The new shares, just 8 days after the listing, announced a net profit of -782 million yuan to -666 million yuan, a decrease of 21.
76% to 3.
73%
.
.
On January 26, another group of pharmaceutical companies released performance forecasts one after another.
Overall, the results were mixed
.
Among them, the performance of 3 companies has risen sharply, 1 company is expected to turn losses, 1 company is expected to decline in performance, 1 company is expected to continue losses, and 2 companies are expected to increase losses
.
Qianhong Pharmaceutical released the 2021 annual report performance forecast.
It is expected that the net profit from 2021-01-01 to 2021-12-31 will be 150 million to 210 million yuan, an increase of 213.
62% to 259.
07%, and basic earnings per share of 0.
12 yuan to 0.
16 yuan
.
Net profit in the same period last year was -132 million yuan, and basic earnings per share was -0.
11 yuan
.
The company said that during the reporting period, the company's main business development trend was good, and product sales revenue increased steadily
.
The 2021 annual report performance forecast released by Betta Pharmaceuticals shows that it is expected to achieve a net profit of 380 million to 430 million yuan in 2021, a decrease of 37.
33% to 29.
09%, and a net profit of 606 million yuan in the same period last year
.
During the reporting period, the company's operating capabilities continued to improve, more than 40 research projects continued to advance, and the R&D investment increased compared with the same period of the previous year.
It is estimated that the R&D investment accounted for about 37.
00% to 42.
00% of the operating income
.
The 2021 annual report performance forecast disclosed by Saisheng Pharmaceutical shows that it is expected to achieve a net profit of 356 million to 403 million yuan from January 1, 2021 to December 31, 2021, an increase of 130% to 160%.
Profit of 155 million yuan
.
In addition, the company expects that the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses in 2021 will decrease by 0%-30% compared with the same period of the previous year.
About 106.
15 million yuan
.
Haier Bio released the 2021 annual report performance forecast.
It is expected that the net profit in 2021 will be 799 million yuan to 894 million yuan, an increase of 109.
77% to 134.
77%, and a net profit of 381 million yuan in the same period last year
.
It is reported that the company has maintained high growth under the premise of ensuring profitability and achieved high-quality development.
.
During the reporting period, with the continuous deepening of the Internet of Things strategy, the company continued to invest in research and development to promote innovative iterations of technology and product solutions, accelerated channel and network expansion to expand its competitive advantages in the global market, and continued to accelerate the ecological layout of IoT scenarios to ensure the best user experience.
Double-high growth in IoT solutions business and traditional business
.
The 2021 annual report performance forecast released by Dizhe Pharmaceuticals shows that it is expected to achieve a net profit of about -670 million yuan from 2021-01-01 to 2021-12-31, a decrease of about 14.
15%, and a net profit of -587 million yuan in the same period last year
.
During the reporting period, all of the company's research products are in the research and development stage, and commercial production and sales have not yet been launched, and the company's products have not yet achieved sales revenue
.
In addition, the company continues to invest funds to launch new products into preclinical research and clinical trials; with the advancement of research and development progress, some products in the product pipeline are gradually entering the critical clinical stage, requiring large-scale research and development investment, resulting in The company's R&D expenses continue to increase
.
Olin Bio's 2021 annual report performance forecast, it is expected that from 2021-01-01 to 2021-12-31, it will obtain a net profit of 100 million to 115 million yuan, an increase of 176.
78% to 218.
29%, and a net profit of 36.
1302 million yuan in the same period last year
.
Regarding the reasons for the changes in performance, the company will continue to increase market development efforts in 2021, and the company's sales of adsorbed tetanus vaccine will continue to grow
.
At the same time, in 2021, the company's group A group C meningococcal polysaccharide conjugate vaccine obtained the first batch of release and marketing, bringing sales revenue to the company
.
In addition, a number of new pharmaceutical stocks released performance forecasts on the same day.
For example, Asieris Pharmaceuticals, which has just been listed for 19 days, announced a net profit of -251 million to -211 million, an increase of -1.
69% to 14.
60%; Maiwei Bio also The new shares, just 8 days after the listing, announced a net profit of -782 million yuan to -666 million yuan, a decrease of 21.
76% to 3.
73%
.
